Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2017 ASCO Annual Meeting!


Session: Developmental Therapeutics—Immunotherapy

Type: Oral Abstract Session

Time: Monday June 5, 1:15 PM to 4:15 PM

Location: Hall D1

Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259t in HLA-A2+ patients with synovial sarcoma (NCT01343043).

Sub-category:
Cellular Immunotherapy

Category:
Developmental Therapeutics—Immunotherapy

Meeting:
2017 ASCO Annual Meeting

Abstract No:
3000

Citation:
J Clin Oncol 35, 2017 (suppl; abstr 3000)

Author(s): Crystal Mackall, William D. Tap, John Glod, Mihaela Druta, Warren Allen Chow, Dejka M. Araujo, Stephan A. Grupp, Brian Andrew Van Tine, Karen Chagin, Erin Van Winkle, Gabor Kari, Trupti Trivedi, Elliot Norry, Tom Holdich, Arundathy N. Bartlett-Pandite, Rafael G. Amado, Sandra P. D'Angelo; Stanford University School of Medicine, Stanford, CA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; National Cancer Institute at the National Institutes of Health, Bethesda, MD; Moffitt Cancer Center, Tampa, FL; City of Hope, Duarte, CA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Pediatric Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA; Washington University in St. Louis, St. Louis, MO; Adaptimmune Therapeutics PLC, Philadelphia, PA; Adaptimmune Therapeutics PLC, Abingdon, United Kingdom

Abstract Disclosures

Abstract:

Background: NY-ESO-1 is expressed in ~70% of synovial sarcomas (SS). NY-ESO-1c259T cells recognizing an NY-ESO-1 derived peptide complexed with HLA-A*02 are being studied in SS. Methods: Eligible patients (pt) are HLA-A*02:01, 02:05 or 02:06, with unresectable, metastatic or recurrent SS expressing NY-ESO-1. Primary endpoint of ORR (CR+PR) is evaluated in high (≥ 50% tumor cells express 2+/3+) and low (≥ 1+ in ≥ 1% cells, not exceeding 2+/3+ in ≥ 50% cells) NY-ESO-1 expressers with different lymphodepleting regimens. Secondary endpoints are safety, DOR, PFS, OS, and gene-marked cell persistence. Lymphocytes are obtained by leukapheresis, isolated, activated, transduced to express NY-ESO-1c259T, and expanded. Target dose is 1–6 × 109cells. Disease is assessed at wk 4, 8 and 12 post-T-cell infusion, and then every 3 months. Results: 34 pt have been enrolled with 24 treated. 50% are male; median age is 30 yr (range 15 – 73). 12/15 pt in cohort 1 were treated. ORR was 50% (1 CR; 5 PR). Time to response was 6 wk (range 4-9) and median DOR 31 wk (range 13-72). Cohort 3 was closed due to only 1 PR out of 5 pt. Evaluation is ongoing in cohorts 2 (6 enrolled; 5 treated) and 4 (8 enrolled; 2 treated) as of 1/9/17. The most common AE are leukopenia (96%), nausea and pyrexia (88%), neutropenia (88%), lymphopenia (83%), anemia (79%), and thrombocytopenia (79%). 11 events of CRS were reported (3 G3; 1 G4), with no events of seizure, cerebral edema or fatal neurotoxicity; all resolved with supportive therapy. One fatal SAE (bone marrow failure) occurred in cohort 2; investigations have not identified a mechanism by which NY-ESO-1c259T may have caused this event. Conclusions: NY-ESO-1c259T has promising efficacy and acceptable safety. CRS is not associated with severe neurotoxicity and appears manageable with appropriate supportive care. Cohort 3 data indicate that Flu may be important for efficacy. Efficacy and safety data will be further evaluated and presented. Clinical trial information: NCT01343043

CohortNY-ESO-1 expressionLymphodepletion
1*highFludarabine (Flu) 30 mg/m2/day × 4
2lowcyclophosphamide (Cy) 1800 mg/m2/day × 2
3*highCy 1800 mg/m2/day × 2
4highFlu 30 mg/m2/day × 3, Cy 600 mg/m2/day ×3

*Closed

 
Other Abstracts in this Sub-Category:

 

1. The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL).

Meeting: 2017 ASCO Annual Meeting Abstract No: 103 First Author: Shannon L. Maude
Category: Developmental Therapeutics—Immunotherapy - Cellular Immunotherapy

 

2. Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.

Meeting: 2017 ASCO Annual Meeting Abstract No: LBA3001 First Author: Frank (Xiaohu) Fan
Category: Developmental Therapeutics—Immunotherapy - Cellular Immunotherapy

 

3. A phase I/II clinical trial of E6 T-cell receptor gene therapy for human papillomavirus (HPV)-associated epithelial cancers.

Meeting: 2017 ASCO Annual Meeting Abstract No: 3009 First Author: Christian S. Hinrichs
Category: Developmental Therapeutics—Immunotherapy - Cellular Immunotherapy

 

More...